Compare Novo Nordisk A/S (NVO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Direxion Daily TSLA Bull 2X Shares trades at $11.27. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| NVO | TSLL | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $71.70 | $23.03 |
52-Week Low | $35.29 | $10.29 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
TSLL is trading at $10.72, down 5.84% over the past day, with a bearish technical signal from moving averages and neutral oscillators. Key support lies at $10 and resistance at $11. The company has announced a future dividend of $0.10 per share scheduled for June 30, 2026. Recent news highlights focus on Tesla's upcoming earnings and related ETF movements, which may influence TSLL's performance given its thematic exposure.
The outlook for TSLL is cautious due to bearish technical indicators and reliance on Tesla's earnings catalyst. Investment opportunities hinge on positive earnings surprises from Tesla boosting the ETF, while risks include continued technical weakness and broader market volatility affecting leveraged ETF performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
